Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy.
Adeno-associated viral (AAV) vectors have demonstrated considerable promise for gene therapy of inherited diseases. However, with a packaging size of <5 kb, applications have been limited to relatively small disease genes. Based on the finding that AAV genomes undergo intermolecular circular concatamerization after transduction in muscle, we have developed a paradigm to increase the size of delivered transgenes with this vector through trans-splicing between two independent vectors coadministered to the same tissue. When two vectors encoding either the 5' or 3' portions of the erythropoietin genomic locus were used, functional erythropoietin protein was expressed in muscle subsequent to the formation of intermolecular circular concatamers in a head-to-tail orientation through trans-splicing between these two independent vector genomes. These findings will allow for the application of AAV technologies to a wider variety of diseases for which therapeutic transgenes exceed the packaging limitation of present AAV vectors.
Yan
Z
Z
Center for Gene Therapy of Cystic Fibrosis and Other Genetic Diseases, University of Iowa College of Medicine, Iowa City, IA 52242, USA.
Zhang
Y
Y
Duan
D
D
Engelhardt
J F
JF
D000740:Anemia / Q000517:prevention & control; D000818:Animals; D000229:Dependovirus / Q000235:genetics*; D004921:Erythropoietin / Q000235:genetics*; D015316:Genetic Therapy; D005822:Genetic Vectors; D007676:Kidney Failure, Chronic / Q000150:complications; D051379:Mice; D008810:Mice, Inbred C57BL; D009132:Muscles / Q000378:metabolism
D004921:Erythropoietin